The HHS renewed the national public health emergency for the monkeypox outbreak in the United States; more demand for amoxicillin has led to a nationwide shortage as respiratory illnesses continue to spread; a drug already approved for weight loss in adults has demonstrated promise in teenagers aged 12 to 17 years.
HHS announced that it is renewing the national public health emergency for the monkeypox outbreak, according to The Hill. The continued consequences of the outbreak in multiple states were cited as the reason to prolong the declared health emergency, as well as the need to maintain the flow of data and allow studies on vaccine effectiveness to continue. This news comes as new studies have found that monkeypox can spread prior to symptoms appearing, according to Reuters, which challenges the previously held belief that monkeypox is primarily spread by people already sick.
A shortage of amioxicillin has been caused by an increase in respiratory illnesses in children throughout the country, according to The Washington Post. Pharmacists say that amoxicillin in some form is still available, but parents may have to visit multiple pharmacies or accept a different strength or form than originally prescribed due to the shortage. The shortage is mostly affecting supplies of the liquid version and some chewable tablet forms. The shortage may last only as long as respiratory syncytial virus (RSV) season does, as the shortage is in large part due to the influx of children admitted to the hospital with a diagnosis of RSV.
A clinical trial found that teenagers with obesity were able to lose weight when using semaglutide (Wegovy), which reduces appetite, according to NBC News. The study found that more than 40% of the participants, aged 12 to 17 years, who received the drug and lifestyle counseling saw a reduction in their body mass index by 20% or more. Semaglutide has previously been found to benefit adults who have type 2 diabetes and has been proven to help weight loss in adults, with the FDA approving the drug for weight loss in 2021. Long-term effectiveness of the drug has yet to be determined.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More